Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Acquired Immunodeficiency Syndrome 1

Interventions

Cytarabine 13fludarabine phosphate 8Etoposide 8Methotrexate 7Idarubicin 6Daunorubicin 6Busulfan 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Vorinostat 4Tacrolimus 4Mitoxantrone 4Cyclophosphamide 4Azacitidine 4Antilymphocyte Serum 4merphos 3Topotecan 3Thioguanine 3Cyclosporine 3sargramostim 2laromustine 2Specimen Handling 2Radiotherapy 2Methylprednisolone 2Lenalidomide 2Hydrocortisone 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anemia, Refractory, with Excess of Blasts × Maraviroc × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡